Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Cipla Secures Ex-FDA Official As Compliance Head

Indian firms have been making extensive efforts to improve their compliance record, including getting on board top-notch global talent. Cipla, which recently appointed a new head of respiratory manufacturing, has tapped an ex-FDA investigator as its audit and compliance director.

Appointments Companies

Boehringer Navigates ‘Impractical’ Nintedanib Surveillance Plan In India

Boehringer seeks tweaks in the surveillance plan for nintedanib in India amid disinclination among some physicians to participate in the study. Some experts though believe that the Indian regulatory apparatus should, in general, specify “strict guidance” on all protocol review requests.

Regulation Review Pathway

Fosun Tweaks Gland Deal Amid Limbo In India

China’s Fosun group isn’t backing off from its $1bn-plus buyout of Gland Pharma and will now pursue a tweaked version of the original deal that technically qualifies for automatic approval under Indian rules. Whether that means smooth sailing hereon remains unclear.

Commercial Deals

Lupin Reviews R&D Thrust, Biosimilars Plan On Course

Lupin is reorienting its R&D priorities with a thrust on more definitive, near and mid-term opportunities while rationalizing its discovery program and trimming its headcount. The firm’s biosimilars program though remains on track with a filing anticipated in Europe and Japan this fiscal.

Commercial Strategy

Will Keytruda Price Differential Really Count In India?

Merck has launched Keytruda at an “India-specific” price but some experts say that the immuno-oncology therapy will likely still be beyond the reach of a majority of patients. Merck though also expects to offer a patient access program for those who can’t afford the therapy.

Commercial Strategy

Indian Generics Firms Must Shift Gears For Third Wave, Says Lupin MD

Indian firms must transition from “plain-vanilla” generics to more complex products, including biosimilars, if they want to continue growing. However, returns from the sector’s so-called Third Wave will be some time coming, warns Lupin’s managing director Nilesh Gupta.

Generic Drugs Business Strategies
See All
Advertisement
UsernamePublicRestriction

Register